🧾 What This Document Is

This is an 8-K filing by NightFood Holdings (ticker: NGTF). Think of an 8-K as a "current events" report that public companies must file with the SEC to announce major news to investors.

The big news here is that NightFood has signed a major joint venture agreement. However, the agreement itself is between two other companies: Oncotelic Therapeutics (an AI biopharma company) and TechForce Robotics (a robotics engineering firm). NightFood is likely filing this because it has a business relationship with one or both companies, or because this deal could significantly impact its own operations or strategy. The attached document is the full, confidential contract.

🤝 The Deal: A New Tech Partnership

This is a Joint Development, Manufacturing, and Licensing Agreement. In simple terms, two companies with different expertise are teaming up to build a single, new product.

👉 The Goal: Combine Oncotelic's AI software (for optimizing drug manufacturing) with TechForce's robotic hardware to create an integrated, automated robot for use in pharmaceutical factories. This system must meet strict "Good Manufacturing Practice" (GMP) regulatory standards.

Why it matters: Drug manufacturing is highly regulated and complex. This partnership aims to create a "smart" robot that not only handles physical tasks but also uses AI to monitor, document, and optimize the entire process, potentially making it faster, cheaper, and less prone to human error.

🧠 The Brains vs. The Brawn: Who Brings What

The partnership is built on a clear division of intellectual property (IP) and expertise.

• Oncotelic (The "Brains"): Owns the PDAOAI Platform, which is their proprietary AI for pharmaceutical process optimization. Their core contribution is the software, algorithms, and data intelligence.
• TechForce (The "Brawn"): Owns the robotic hardware, mechanical engineering, and automation systems. Their core contribution is the physical robot and its control systems.

👉 The key rule: Each company keeps full ownership of its existing technology ("Background IP"). Anything new they invent together ("Foreground IP") is owned based on what was invented: AI-related inventions belong to Oncotelic, pure hardware inventions belong to TechForce, and truly joint inventions are co-owned.

💰 The Financial Framework (But the Big Numbers Are Still TBD)

The agreement sets the rules for money but doesn't specify the final amounts. It's a framework for future negotiation.

• Development Funding: Each party will pay for its own assigned tasks as outlined in separate statements of work.
• Milestone Payments: Payments will be triggered when specific development goals are hit (e.g., a working prototype is accepted).
• Royalties & Profit Sharing: This is the biggest unknown. The crucial financial terms—like how they split revenue from sales or subscriptions—are to be negotiated in a separate "Commercialization and Licensing Agreement" (CLA) before the product can be sold. No sales can happen until that deal is signed.

Why it matters: Investors can see the partnership's structure, but the actual profitability for NightFood (or the involved parties) hinges on the future CLA. It’s like having a blueprint for a factory but not yet knowing the price of the goods it will produce.

🔒 Who Owns the Data? (A Critical Point)

A hugely important section deals with data ownership. All data generated by the robot when it's operating in a factory—like performance logs, process data, and AI insights—will be owned exclusively by Oncotelic.

👉 TechForce is strictly forbidden from using this data for its own purposes, like training its own AI models or selling it to others. This is a major protective measure for Oncotelic's core business.

⏳ What Happens Next & How It Ends

The agreement has a clear timeline and exit plan.

• Term: It starts with a 1-year term, then automatically renews for 5-year periods unless either side cancels.
• Termination: Either side can cancel for any reason with 60 days' notice. They can also terminate immediately for a major breach (like failing to deliver key milestones or going bankrupt).
• If They Break Up: Existing customer orders must still be filled. Each company gets its own technology back. They must return or destroy the other's confidential information. The rights to use each other's IP for the project end, except to wind down current business.

⚖️ Risks & Protections

The contract is filled with standard legal protections to manage a complex partnership.

• Exclusivity: TechForce is barred for 12 months after the deal ends from licensing the jointly developed product to a competitor in pharma. It can still sell its own separate robots to anyone.
• Liability: Each side is responsible for indemnifying (legally protecting) the other from losses caused by their own mistakes or IP infringements. Liability is capped, typically at the greater of $1 million or one year's fees paid.
• Disputes: Arguments must go through a three-step process: executive talk, then mediation, and finally binding arbitration in California.

🧠 The Analogy

This deal is like a high-end restaurant (Oncotelic) partnering with a top appliance manufacturer (TechForce). The restaurant provides the secret recipe and culinary expertise (the AI platform), while the manufacturer builds the custom, state-of-the-art oven (the robotic system). The restaurant will own all the cooking data from the oven. They plan to sell these oven-recipe combos to other restaurants, but they haven't yet decided how to split the profits from those future sales. If the partnership dissolves, the recipe stays with the chef, and the oven design stays with the manufacturer.

🧩 Final Takeaway

NightFood is announcing a strategic tech partnership where an AI-pharma company and a robotics company are merging their expertise to build an AI-powered robot for drug manufacturing. The deal sets up who owns what (especially the critical data), but leaves the most important financial terms—how money from future sales will be shared—for a separate agreement to be negotiated later. This is a foundational step, with the real commercial details still to come.